Royalty Pharma plc
Christopher Hite (EVP & Chairman, Partnering) reports RPRX insider transactions
AI-generated summary
Christopher Hite, EVP & Chairman, Partnering of Royalty Pharma plc Class A Ordinary Shares, received 7,122 shares as a grant on November 4, 2026. Following this transaction, the insider indirectly holds 277,523 shares by SCH Investment Partners LLC.
Key facts
- Insider
- Christopher Hite · EVP & Chairman, Partnering
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | A · grantFootnotes F1 | +7,122 | $0.00 | $0.00 | 277,523 | Indirect (By SCH Investment Partners LLC) |
Footnotes
- F1 Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
Remarks: In addition to the Class A Ordinary Shares disclosed above, family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 866,410 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,238,789 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.
More RPRX filings
- 4
Filed Nov 6, 2026
- 4
Filed Nov 6, 2026
- 4
Filed Nov 6, 2026
- SC 13G/A
Filed Nov 5, 2026
- 10-Q
Filed Nov 4, 2026
- 8-K
Filed Nov 4, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.